GlassScriptPhysician profile
Stephen Schleicher
NPI 1336433549
$26,011.41
in general payments reported to CMS, 2019-2025
50 companies · $948 in 2025
The $948 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $351 · 2021: $24.37 · 2022: $1,074 · 2023: $529 · 2024: $11K · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,370 · Food and Beverage: $1,675 · Travel and Lodging: $1,158 · Education: $41.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,370.00 |
| Food and Beverage | $1,674.59 |
| Travel and Lodging | $1,157.80 |
| Education | $41.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $10,527.80 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $5,607.75 | 2019-2025 | Datroway |
| Rigel Pharmaceuticals, INC. | $2,902.19 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,652.71 | 2019-2022 | |
| Amgen INC. | $724.27 | 2019-2023 | Xgeva |
| Merck Sharp & Dohme LLC | $493.43 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $330.05 | 2019-2025 | Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $261.59 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $237.85 | 2022-2024 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Genzyme Corporation | $208.66 | 2019-2025 | |
| Genentech USA, INC. | $207.02 | 2019-2020 | |
| Ge Healthcare | $204.15 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $191.48 | 2019-2025 | Opdivo |
| Kite Pharma, INC. | $176.75 | 2025 | Yescarta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schleicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.